terican

Last verified · v1.0

Calculator · health

Vaccine Efficacy Calculator

Compute vaccine efficacy (VE) from trial data using the CDC-standard attack rate formula. Enter case counts for vaccinated and control groups.

FreeInstantNo signupOpen source

Inputs

Vaccine Efficacy

—

Explain my result

0/3 free

Get a plain-English breakdown of your result with practical next steps.

Vaccine Efficacy—

The formula

How the
result is
computed.

What Is Vaccine Efficacy?

Vaccine efficacy (VE) is the percentage reduction in disease incidence among a vaccinated group compared to an unvaccinated control group under controlled clinical trial conditions. It answers the fundamental question: how much does this vaccine reduce a person's risk of contracting the disease? A VE of 90% means that vaccinated trial participants experienced 90% fewer confirmed cases than their unvaccinated counterparts, all else being equal.

The Vaccine Efficacy Formula

The standard calculation, codified by the CDC's Principles of Epidemiology (Lesson 3, Section 6), derives VE from the attack rates of each study group:

VE = (1 − ARV ÷ ARU) × 100%

  • ARV (Attack Rate in Vaccinated) = vaccinated_cases ÷ vaccinated_total
  • ARU (Attack Rate in Unvaccinated) = unvaccinated_cases ÷ unvaccinated_total

The ratio ARV ÷ ARU represents the relative risk of disease among vaccinated individuals relative to unvaccinated individuals. Subtracting this ratio from 1 yields the fraction of risk eliminated by vaccination, expressed as a percentage. When ARV equals zero — no cases in the vaccinated group — VE reaches its maximum of 100%.

Understanding Each Variable

Cases in Vaccinated Group

The count of confirmed disease cases observed among vaccinated trial participants. Accurate case ascertainment requires standardized diagnostic criteria applied uniformly across both groups to prevent ascertainment bias from inflating or deflating the VE estimate.

Total Vaccinated Population

All subjects enrolled in the vaccinated arm of the trial, regardless of outcome. This denominator converts the raw case count into an attack rate — the proportion who fell ill — making comparisons across differently sized groups valid.

Cases in Unvaccinated Group

Confirmed disease cases among placebo or control recipients. This group establishes the baseline disease burden — what the incidence looks like without vaccination — against which the vaccine's protective effect is measured.

Total Unvaccinated Population

All subjects in the control arm. For unbiased VE estimates, both groups should be comparable in size, age distribution, comorbidity profile, and exposure risk. Imbalances in these factors can confound the result.

Step-by-Step Example: mRNA COVID-19 Vaccine Trial

The Phase 3 Pfizer-BioNTech trial offers one of the most cited applications of this formula:

  • Vaccinated group: 8 cases among 18,198 participants → ARV = 8 ÷ 18,198 = 0.000440
  • Unvaccinated group: 162 cases among 18,325 participants → ARU = 162 ÷ 18,325 = 0.008840
  • VE = (1 − 0.000440 ÷ 0.008840) × 100% = (1 − 0.04977) × 100% ≈ 95.0%

This means vaccinated participants faced approximately 95% lower risk of symptomatic COVID-19. The 95% confidence interval of 90.3%–97.6% confirmed robust statistical significance across the full sample.

Interpreting VE Results

Vaccine efficacy values span a meaningful spectrum:

  • VE = 100%: Zero cases in the vaccinated group — complete protection in the trial
  • VE ≥ 50%: Meets the WHO minimum benchmark for emergency use authorization consideration
  • VE = 0%: The vaccine conferred no measurable protection
  • VE < 0%: Vaccinated individuals experienced higher disease incidence — a rare signal warranting investigation for vaccine-enhanced disease or methodological error

Vaccine Efficacy vs. Vaccine Effectiveness

Efficacy and effectiveness are related but distinct concepts. As detailed in the mathematical analysis published in Illinois State University's journal Spora, efficacy describes performance under ideal trial conditions, while effectiveness captures real-world performance under routine immunization programs. Real-world effectiveness typically runs lower than trial efficacy due to cold-chain variability, heterogeneous population health, evolving pathogen variants, and waning immunity over time.

Confidence Intervals and Statistical Reliability

A point estimate of VE is only part of the picture. As demonstrated in the analysis of COVID-19 vaccine confidence intervals published by the University of South Florida, the width of the 95% confidence interval around a VE estimate reflects the certainty of the finding. Large trials with many observed cases produce narrow intervals — strong evidence of true protection. Small trials or low disease incidence can yield wide intervals, making the VE estimate unreliable for policy decisions even if the point estimate appears favorable.

Limitations of the VE Calculation

The standard VE formula assumes equal surveillance intensity across both groups, a consistent case definition, no crossover between arms, and a follow-up period long enough to observe meaningful incidence. Violation of any assumption can bias the estimate. Waning immunity and variant-specific protection are also not captured in a single aggregate VE figure — time-stratified or strain-specific analyses are needed to account for these dynamics.

Reference

Frequently asked questions

What does a vaccine efficacy of 95% actually mean?
A vaccine efficacy of 95% means vaccinated trial participants developed 95% fewer confirmed disease cases than unvaccinated participants over the same period. For example, if 100 out of 10,000 unvaccinated individuals contracted the disease, a 95% VE predicts roughly 5 cases per 10,000 vaccinated individuals. The figure describes relative risk reduction in a controlled trial, not the absolute probability any individual will remain healthy after vaccination.
What is the difference between vaccine efficacy and vaccine effectiveness?
Vaccine efficacy is measured in randomized controlled trials under carefully monitored conditions, with balanced groups and standardized diagnostics. Vaccine effectiveness is measured after deployment in routine immunization programs, where populations are diverse, storage conditions vary, and new pathogen variants may circulate. Effectiveness is nearly always lower than efficacy because ideal trial conditions cannot be replicated at population scale. Both metrics use the same core attack-rate formula but draw from very different data sources.
How is the attack rate used in the vaccine efficacy formula?
The attack rate for each group equals the number of disease cases divided by the total group size. For instance, if 15 vaccinated individuals out of 6,000 developed disease, the attack rate in the vaccinated group is 15 divided by 6,000, equaling 0.0025 or 0.25%. The same calculation is applied to the unvaccinated group. Dividing the vaccinated attack rate by the unvaccinated attack rate yields the relative risk, and subtracting that from 1 gives vaccine efficacy.
What sample size is needed for a statistically reliable vaccine efficacy estimate?
Reliable VE estimates generally require thousands of participants per arm and a minimum of 50 to 150 confirmed cases across both groups to produce confidence intervals narrow enough for regulatory decisions. The precise number depends on the disease attack rate in the control population, the target VE threshold, and the desired statistical power — commonly set at 90%. For rare diseases with low background incidence, trials may need 30,000 or more total participants to observe sufficient cases.
Can vaccine efficacy be negative, and what does that indicate?
Yes, a negative VE result is mathematically possible and means the attack rate in the vaccinated group exceeded the attack rate in the unvaccinated group. This can reflect vaccine-enhanced disease — a phenomenon where vaccination inadvertently increases susceptibility or severity — or it can stem from methodological problems such as unequal follow-up time, differential case ascertainment, or confounding by exposure risk. Negative efficacy in an approved vaccine is extremely rare and triggers immediate regulatory review.
What WHO threshold must a vaccine meet to qualify for emergency use authorization?
The World Health Organization's target product profile for most vaccines specifies a minimum efficacy point estimate of 50%, with the lower bound of the 95% confidence interval exceeding 30%. This threshold ensures that even accounting for statistical uncertainty, the vaccine provides a meaningful public health benefit. Regulatory bodies such as the U.S. FDA and the European EMA apply similar or stricter criteria, and may also require evidence of efficacy across key subgroups including older adults and immunocompromised populations.